Abstract
Krüppel-like transcription factor 10 (KLF10), also named as TIEG1, plays essential roles in mediating transforming growth factor beta (TGFβ) signaling and has been shown to function as a tumor suppressor in multiple cancer types. However, its roles in mediating cancer progression in vivo have yet to be fully characterized. Here, we have employed two well-characterized Pdx-1CreLSL-KrasG12D and Pdx-1CreLSL-KrasG12Dp53L/L pancreatic cancer models to ablate KLF10 expression and determine the impact of KLF10 deletion on tumor development and progression. We show that loss of KLF10 cooperates with KrasG12D leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma (PDAC). Mechanistically, loss of KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways. Furthermore, we demonstrate that targeting the SDF-1/CXCR4 pathway in the context of KLF10 deletion substantially suppresses PDAC progression suggesting that inhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA . Genetics and biology of pancreatic ductal adenocarcinoma. Genes dev 2006; 20: 1218–1249.
Hidalgo M . Pancreatic cancer. N Engl j med 2010; 362: 1605–1617.
Chen LT, Wang-Gillam A, Von Hoff DD, Bayever E, Belanger B . Nanoliposomal irinotecan in metastatic pancreatic cancer—authors' reply. Lancet 2016; 387: 1997.
Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA: Cancer j clin 2010; 60: 277–300.
Bardeesy N, DePinho RA . Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897–909.
Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947–5952.
Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes dev 2003; 17: 3112–3126.
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell 2003; 4: 437–450.
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer cell 2005; 7: 469–483.
Massaous J, Hata A . TGF-beta signalling through the Smad pathway. Trends cell biol 1997; 7: 187–192.
Romero-Gallo J, Sozmen EG, Chytil A, Russell WE, Whitehead R, Parks WT et al. Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene 2005; 24: 3028–3041.
Siegel PM, Massague J . Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807–821.
Iacopetta BJ, Welch J, Soong R, House AK, Zhou XP, Hamelin R . Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: relationship to clinicopathological features and genetic alterations. J pathol 1998; 184: 390–395.
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336–1338.
Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE et al. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer res 2004; 64: 4523–4530.
David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N et al. TGF-beta tumor suppression through a lethal EMT. Cell 2016; 164: 1015–1030.
Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–196.
Subramaniam M, Harris SA, Oursler MJ, Rasmussen K, Riggs BL, Spelsberg TC . Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic acids res 1995; 23: 4907–4912.
Subramaniam M, Hawse JR, Rajamannan NM, Ingle JN, Spelsberg TC . Functional role of KLF10 in multiple disease processes. BioFactors 2010; 36: 8–18.
Hawse JR, Iwaniec UT, Bensamoun SF, Monroe DG, Peters KD, Ilharreborde B et al. TIEG-null mice display an osteopenic gender-specific phenotype. Bone 2008; 42: 1025–1031.
Tau KR, Hefferan TE, Waters KM, Robinson JA, Subramaniam M, Riggs BL et al. Estrogen regulation of a transforming growth factor-beta inducible early gene that inhibits deoxyribonucleic acid synthesis in human osteoblasts. Endocrinology 1998; 139: 1346–1353.
Jin W, Chen BB, Li JY, Zhu H, Huang M, Gu SM et al. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol cell biol 2012; 32: 50–63.
Spittau G, Happel N, Behrendt M, Chao TI, Krieglstein K, Spittau B . Tieg1/Klf10 is upregulated by NGF and attenuates cell cycle progression in the pheochromocytoma cell line PC12. J Neurosci Res 2010; 88: 2017–2025.
Hawse JR, Subramaniam M, Monroe DG, Hemmingsen AH, Ingle JN, Khosla S et al. Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol endocrinol 2008; 22: 1579–1595.
Spittau B, Krieglstein K . Klf10 and Klf11 as mediators of TGF-beta superfamily signaling. Cell Tissue Res 2012; 347: 65–72.
Papadakis KA, Krempski J, Reiter J, Svingen P, Xiong Y, Sarmento OF et al. Kruppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-beta signaling in CD8+ T lymphocytes. Am J Physiol Cell Physiol 2015; 308: C362–C371.
Tachibana I, Imoto M, Adjei PN, Gores GJ, Subramaniam M, Spelsberg TC et al. Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J clin invest 1997; 99: 2365–2374.
Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635–638.
Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998; 95: 9448–9453.
Feng Y, Broder CC, Kennedy PE, Berger EA . HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872–877.
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK . CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin cancer res 2011; 17: 2074–2080.
Chang VH, Chu PY, Peng SL, Mao TL, Shan YS, Hsu CF et al. Kruppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma. Am J Pathol 2012; 181: 423–430.
Hruban RH, Goggins M, Parsons J, Kern SE . Progression model for pancreatic cancer. Clin cancer res 2000; 6: 2969–2972.
Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851–856.
Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 2014; 123: 3296–3304.
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl j med 2011; 364: 1817–1825.
Derynck R, Akhurst RJ, Balmain A . TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117–129.
Massague J . TGFbeta in cancer. Cell 2008; 134: 215–230.
Padua D, Massague J . Roles of TGFbeta in metastasis. Cell res 2009; 19: 89–102.
Johnsen SA, Subramaniam M, Monroe DG, Janknecht R, Spelsberg TC . Modulation of transforming growth factor beta (TGFbeta)/Smad transcriptional responses through targeted degradation of TGFbeta-inducible early gene-1 by human seven in absentia homologue. J biol chem 2002; 277: 30754–30759.
Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC . TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses. Oncogene 2002; 21: 5783–5790.
Cao Z, Wara AK, Icli B, Sun X, Packard RR, Esen F et al. Kruppel-like factor KLF10 targets transforming growth factor-beta1 to regulate CD4(+)CD25(-) T cells and T regulatory cells. J biol chem 2009; 284: 24914–24924.
Jiang L, Chen Y, Chan CY, Wang X, Lin L, He ML et al. Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer lett 2009; 274: 101–108.
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T . Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744–749.
Kalluri R, Neilson EG . Epithelial–mesenchymal transition and its implications for fibrosis. J clin invest 2003; 112: 1776–1784.
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527: 525–530.
Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA . A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J exp med 1996; 184: 1101–1109.
Singh S, Singh UP, Grizzle WE, Lillard JW Jr. . CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab invest 2004; 84: 1666–1676.
Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH . Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma. Vet Comp Oncol 2017; 15: 315–327.
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335–348.
Cui K, Zhao W, Wang C, Wang A, Zhang B, Zhou W et al. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J surg res 2011; 171: 143–150.
Mukherjee D, Zhao J . The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am j cancer res 2013; 3: 46–57.
Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R et al. Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin cancer res 2008; 14: 3627–3632.
Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J clin oncol 2004; 22: 1095–1102.
Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206–6214.
Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ et al. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol 2014; 234: 190–202.
Acknowledgements
This work was supported by grants MOST 104-2320-B-110-003 and 105-2320 -B-110-004 (to KH Cheng), MOST 101-2628-B-400-003-MY2 (to LT Chen) and MOST 105-2321-B-400-010 (to LT Chen and KH Cheng) from the Ministry of Science and Technology, Taiwan ROC, and grants KMU-TP104G00, KMU-TP105G00 (to KH Cheng) from Kaohsiung Medical University, Kaohsiung, Taiwan, and grant R01 DE14036 (to JRH and MS) from the National Institutes of Health, USA.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Weng, CC., Hawse, J., Subramaniam, M. et al. KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model. Oncogene 36, 5532–5543 (2017). https://doi.org/10.1038/onc.2017.155
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2017.155
This article is cited by
-
Krüppel-like factor 10 modulates stem cell phenotypes of pancreatic adenocarcinoma by transcriptionally regulating notch receptors
Journal of Biomedical Science (2023)
-
Genome-wide aberrant methylation in primary metastatic UM and their matched metastases
Scientific Reports (2022)
-
Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency
Experimental & Molecular Medicine (2021)
-
ERas regulates cell proliferation and epithelial–mesenchymal transition by affecting Erk/Akt signaling pathway in pancreatic cancer
Human Cell (2020)
-
Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer
Molecular Cancer (2019)